Previously treated CAR-T patients

GENETIC2 trials

Sponsors

Novartis Pharma. K.K., Novartis Pharmaceuticals

Conditions

Any patients have received a Novartis or Penn CAR-T therapyLong Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program

Phase 3

CAR-T Long Term Follow Up (LTFU) Study

RecruitingNCT02445222

Novartis PharmaceuticalsLong Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program

Start: 2015-11-02End: 2036-02-22Target: 1400Updated: 2025-10-28

Unknown Phase

CAR-T Long Term Follow Up Study

RecruitingJPRN-jRCT1080225004

Novartis Pharma. K.K.Any patients have received a Novartis or Penn CAR-T therapy

Start: 2020-01-15Target: 14Updated: 2026-06-29

Related Papers

Long Term Durable Responses in Relapsed/Refractory (r/r) ALL, DLBCL, and FL Patients Treated with Tisagenlecleucel and Its Association with Persistence of CAR T-Cells

Blood2023-11-024 citations

Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol

BMJ Open2019-05-0140 citations